Our report provides insight on this new therapeutic class and suggests strategies for managing it
A new class of medications known as calcitonin gene-related peptide (CGRP) inhibitors are being developed explicitly for the prevention of migraines, with one drug recently receiving Food and Drug Administration (FDA) approval. While migraines affect approximately 14% of adults in the United States, up to this point there were no medications developed specifically to prevent their occurrence. What now?
Download our Perspective on the Rx Pipeline report to learn more about:
EnvisionPharmacies is committed to helping payers understand the impact of this new therapeutic class and supporting patients who start taking CGRP inhibitors. For more information, visit envisionpharmacies.com.